Home > Boards > US Listed > Medical - Healthcare > Mylan Inc. (MYL)

A news article mentioning Mylan.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Tlsmd Member Profile
 
Followed By 61
Posts 7,312
Boards Moderated 0
Alias Born 06/21/14
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2019 1:09:35 PM
Novartis to Supply EpiPen Alternate to U.S. Pharmacies -Reuters Dow Jones News - 7/9/2019 7:30:00 PM
Mylan and Atomo Diagnostics Announce WHO Prequalification Approval for Mylan HIV Self Test PR Newswire (US) - 7/8/2019 12:42:00 PM
Medexus Appoints Accomplished Global Pharmaceutical Industry Executive Adele M. Gulfo to its Board of Directors GlobeNewswire Inc. - 6/25/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/21/2019 5:02:33 PM
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China an... PR Newswire (US) - 6/14/2019 8:05:00 AM
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China an... PR Newswire (US) - 6/14/2019 8:05:00 AM
Notice of Exempt Solicitation Pursuant to Rule 14a6(g) (px14a6n) Edgar (US Regulatory) - 6/13/2019 12:59:29 PM
Notice of Exempt Solicitation Pursuant to Rule 14a6(g) (px14a6n) Edgar (US Regulatory) - 6/7/2019 1:30:36 PM
Notice of Exempt Solicitation Pursuant to Rule 14a6(g) (px14a6n) Edgar (US Regulatory) - 5/31/2019 7:14:02 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 5/24/2019 5:13:35 PM
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International... PR Newswire (US) - 5/20/2019 10:15:00 AM
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International... PR Newswire (US) - 5/20/2019 10:15:00 AM
Mylan Presents Equivalence and Device Usability Data on Wixela™ Inhub™ Compared to Advair Diskus® at American Thoracic S... PR Newswire (US) - 5/18/2019 10:45:00 AM
Mylan to Host Investor Day on July 31, 2019 in New York City PR Newswire (US) - 5/17/2019 8:00:00 AM
Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the... PR Newswire (US) - 5/15/2019 5:01:00 PM
Mylan Expands Oncology Portfolio with Launch of Generic Tarceva® Tablets PR Newswire (US) - 5/10/2019 9:45:00 AM
Mylan to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference PR Newswire (US) - 5/10/2019 8:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 5/10/2019 6:08:13 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2019 11:07:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2019 8:37:17 AM
Mylan Reports First Quarter 2019 Results and Reaffirms 2019 Guidance PR Newswire (US) - 5/7/2019 8:30:00 AM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/30/2019 4:44:34 PM
Mylan to Release First Quarter 2019 Financial Results on May 7, 2019 PR Newswire (US) - 4/26/2019 7:30:00 AM
TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens ... PR Newswire (US) - 4/18/2019 8:00:00 AM
Tlsmd   Sunday, 12/03/17 06:06:56 AM
Re: None
Post # of 141 
A news article mentioning Mylan. Tlsmd

UPDATE: Mylan and Teva stocks rise on report about Amazon's pharmacy aims
19 hours 53 minutes ago - DJNF
By Emily Bary

Drugstores shares fall as they are viewed as vulnerable to Amazon's aims

Shares of generic drug manufacturers rose Friday following a report Amazon.com Inc. has held conversations with Mylan NV and Sandoz, a Novartis AG unit, about potentially entering the pharmacy market.

Meanwhile, drugstores, pharmacy-benefit managers, and distributors are seeing their stocks fall amid concerns that Amazon will provide new competition and disrupt their business models.

CNBC reported late Thursday (https://www.cnbc.com/2017/11/30/amazon-holding-exploratory-talks-with-generic-drug-makers.html) that the Mylan and Sandoz have engaged in "high level" talks and added that it is still unclear what Amazon's(AMZN) pharmacy ambitions are.

"This means that Amazon may be simultaneously exploring either opening a retail pharmacy or drug distribution business," analyst Brian Nowak at Morgan Stanley wrote in a note to clients.

He said the next potential signposts to watch for are Amazon opening a pharmacy inside a Whole Foods Market store and a filing for pharmacy and drug licenses.

Don't miss: Amazon's getting into the pharmacy business is a 'matter of when, not if.' (http://www.marketwatch.com/story/amazons-getting-into-the-pharmacy-business-is-a-matter-of-when-not-if-2017-10-06)

(http://www.marketwatch.com/story/amazons-getting-into-the-pharmacy-business-is-a-matter-of-when-not-if-2017-10-06)Also read: Amazon wants to disrupt the neighborhood pharmacy--but its sketchy health products could get in the way (http://www.marketwatch.com/story/amazons-sketchy-health-products-could-hurt-its-big-pharmacy-ambitions-2017-11-20).

Mylan's(MYL) stock shot up 4.4% to a three-week closing high, while Novartis'(NOVN.EB) shares edged up 0.3%.

Among others in the generic drug business, shares of Teva Pharmaceutical Industries(TEVA) hiked up 3.0% and Endo International(ENDP)(ENDP)(ENDP) rallied 1.4%.

Among drugstore chains, shares of Rite Aid Corp.(RAD) slumped 4.5%, Walgreens Boots Alliance(WBA)shed 1.8% and CVS Health Corp.(CVS) dropped 1.9%.

Shares of distributors were mostly lower, as McKesson Corp.(MCK) was down 0.9% and Cardinal Health Inc.(CAH)gave up 0.5%, while Amerisource Bergen Corp.(ABC) erased early losses to close up 0.2%.

Pharmacy-benefit manager Express Scripts (ESRX) is considered by some to be a potential partner for Amazon (http://www.marketwatch.com/story/amazons-getting-into-the-pharmacy-business-is-a-matter-of-when-not-if-2017-10-06), but its stock fell 1.2%.

"The economics around generic drugs are unique within the supply chain and might make them more attractive for Amazon than trying to sell other brand or specialty drugs where prices are set and then negotiated by pharmacy-benefit managers," wrote Needham analyst Kevin Caliendo in a note to clients. He added that Amazon "still likely will need to acquire a mail order pharmacy or small pharmacy benefit manager to get the licenses needed to distribute and/or dispense drugs on a state-by-state basis."

Amazon's stock fell 1.2% Friday. It was still up 55% so far in 2017, compared with an 18 % gain for the S&P 500 index .

-Emily Bary; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

December 02, 2017 10:00 ET (15:00 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.

« Back to Stocks News

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist